Kenai Therapeutics
This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be implanted into the brain of study participants during a surgical procedure.
Idiopathic Parkinson´s Disease
Parkinson's Disease
RNDP-001
Syringe Front-Loading Device
PHASE1
PHASE2
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 12 participants |
| Masking : | NONE |
| Primary Purpose : | TREATMENT |
| Official Title : | A Phase 1b/2a Study Assessing the Safety and Efficacy of Intraputamenal Dopaminergic Stem Cell Transplants in Patients With Idiopathic Parkinson's Disease |
| Actual Study Start Date : | 2025-07-17 |
| Estimated Primary Completion Date : | 2027-09 |
| Estimated Study Completion Date : | 2031-06 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 45 Years to 75 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
University of Arizona
Tucson, arizona, United States, 85721
RECRUITING
Keck Medical Center of University of Southern California
Los Angeles, California, United States, 90033
RECRUITING
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States, 43210